Similar articles

• Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.

  Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, Bologna M. Festuccia C, et al. J Urol. 2008 Jul;180(1):367-72. doi: 10.1016/j.juro.2008.02.036. Epub 2008 May 22. J Urol. 2008. PMID: 18499161
• Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

  Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS. Andriole GL, et al. J Urol. 2004 Sep;172(3):915-9. doi: 10.1097/01.ju.0000136430.37245.b9. J Urol. 2004. PMID: 15310997 Clinical Trial.
• Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.

  Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Xu Y, et al. Clin Cancer Res. 2006 Jul 1;12(13):4072-9. doi: 10.1158/1078-0432.CCR-06-0184. Clin Cancer Res. 2006. PMID: 16818707
• Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.

  Vis AN, Schröder FH. Vis AN, et al. BJU Int. 2009 Nov;104(9):1191-7. doi: 10.1111/j.1464-410X.2009.08743.x. Epub 2009 Jul 14. BJU Int. 2009. PMID: 19624596 Review.
• 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.

  Dörsam J, Altwein J. Dörsam J, et al. Prostate Cancer Prostatic Dis. 2009;12(2):130-6. doi: 10.1038/pcan.2008.56. Epub 2008 Nov 25. Prostate Cancer Prostatic Dis. 2009. PMID: 19030020 Review.